

## SPECIALTY QUANTITY LIMIT PROGRAM

### SKYRIZI (risankizumab-rzaa)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

#### II. COVERED QUANTITIES

| Medication   | Standard Limit          | Exception Limit*       | FDA-recommended dosing   |
|--|-------------------------|------------------------|--|
| Skyrizi<br>(risankizumab-rzaa)<br>75 mg/0.83 mL<br>prefilled syringe | 2 syringes per 12 weeks | 4 syringes per 28 days | 150 mg (two 75 mg injections) at weeks 0, 4, and every 12 weeks thereafter |

\*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

#### III. REFERENCES

1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; April 2019.